Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Molecular mediators of hepatic steatosis and liver injury.

Browning JD, Horton JD.

J Clin Invest. 2004 Jul;114(2):147-52. Review.

2.

[Patomechanisms of hepatic steatosis].

Fülöp P, Paragh G.

Orv Hetil. 2010 Feb 28;151(9):323-9. doi: 10.1556/OH.2010.28816. Review. Hungarian.

PMID:
20159747
3.
4.

[Etiopathogenesis of non-alcoholic steatohepatitis].

Pérez-Aguilar F.

Gastroenterol Hepatol. 2005 Aug-Sep;28(7):396-406. Review. Spanish.

PMID:
16137475
5.

Mechanisms of intrahepatic triglyceride accumulation.

Ress C, Kaser S.

World J Gastroenterol. 2016 Jan 28;22(4):1664-73. doi: 10.3748/wjg.v22.i4.1664. Review.

6.

Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.

Verna EC, Berk PD.

Semin Liver Dis. 2008 Nov;28(4):407-26. doi: 10.1055/s-0028-1091985. Epub 2008 Oct 27. Review.

PMID:
18956297
7.

Pathogenesis of steatohepatitis.

Day CP.

Best Pract Res Clin Gastroenterol. 2002 Oct;16(5):663-78. Review.

PMID:
12406438
8.

Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.

Choi SS, Diehl AM.

Curr Opin Lipidol. 2008 Jun;19(3):295-300. doi: 10.1097/MOL.0b013e3282ff5e55. Review.

PMID:
18460922
9.

Insulin resistance and steatosis in humans.

Capeau J.

Diabetes Metab. 2008 Dec;34(6 Pt 2):649-57. doi: 10.1016/S1262-3636(08)74600-7. Review.

PMID:
19195626
10.

Update on nonalcoholic fatty liver disease.

McCullough AJ.

J Clin Gastroenterol. 2002 Mar;34(3):255-62. Review.

PMID:
11873108
11.

Fatty liver as a consequence and cause of insulin resistance: lessons from type 2 diabetic liver.

Takamura T, Misu H, Ota T, Kaneko S.

Endocr J. 2012;59(9):745-63. Epub 2012 Aug 12. Review.

12.

Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation.

Tevar AD, Clarke C, Wang J, Rudich SM, Woodle ES, Lentsch AB, Edwards ML.

J Am Coll Surg. 2010 Apr;210(4):515-26. doi: 10.1016/j.jamcollsurg.2010.01.020. Review. No abstract available.

13.

Current pharmacological treatment of nonalcoholic fatty liver.

Portincasa P, Grattagliano I, Palmieri VO, Palasciano G.

Curr Med Chem. 2006;13(24):2889-900. Review.

PMID:
17073635
14.

Nonalcoholic fatty liver disease in pediatric patients.

Sinatra FR.

JPEN J Parenter Enteral Nutr. 2012 Jan;36(1 Suppl):43S-8S. doi: 10.1177/0148607111421610. Review.

PMID:
22237875
15.

Pathophysiology of nonalcoholic steatohepatitis.

McCullough AJ.

J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S17-29. Review.

PMID:
16540762
16.

Novel insights into the pathophysiology of nonalcoholic fatty liver disease.

Feldstein AE.

Semin Liver Dis. 2010 Nov;30(4):391-401. doi: 10.1055/s-0030-1267539. Epub 2010 Oct 19. Review.

PMID:
20960378
17.

Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis.

Koo SH.

Clin Mol Hepatol. 2013 Sep;19(3):210-5. doi: 10.3350/cmh.2013.19.3.210. Epub 2013 Sep 30. Review.

18.

Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.

Cusi K.

Gastroenterology. 2012 Apr;142(4):711-725.e6. doi: 10.1053/j.gastro.2012.02.003. Epub 2012 Feb 8. Review.

PMID:
22326434
19.

Endoplasmic reticulum stress in nonalcoholic fatty liver disease.

Pagliassotti MJ.

Annu Rev Nutr. 2012 Aug 21;32:17-33. doi: 10.1146/annurev-nutr-071811-150644. Review.

PMID:
22809102
20.

Etiopathogenesis of nonalcoholic steatohepatitis.

Chitturi S, Farrell GC.

Semin Liver Dis. 2001;21(1):27-41. Review.

PMID:
11296694

Supplemental Content

Support Center